153 related articles for article (PubMed ID: 19337629)
21. Short-term stability of subtypes in the irritable bowel syndrome: prospective evaluation using the Rome III classification.
Engsbro AL; Simren M; Bytzer P
Aliment Pharmacol Ther; 2012 Feb; 35(3):350-9. PubMed ID: 22176384
[TBL] [Abstract][Full Text] [Related]
22. Mucosal mast cell counts correlate with visceral hypersensitivity in patients with diarrhea predominant irritable bowel syndrome.
Park JH; Rhee PL; Kim HS; Lee JH; Kim YH; Kim JJ; Rhee JC
J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 1):71-8. PubMed ID: 16706815
[TBL] [Abstract][Full Text] [Related]
23. Effects of chili on postprandial gastrointestinal symptoms in diarrhoea predominant irritable bowel syndrome: evidence for capsaicin-sensitive visceral nociception hypersensitivity.
Gonlachanvit S; Mahayosnond A; Kullavanijaya P
Neurogastroenterol Motil; 2009 Jan; 21(1):23-32. PubMed ID: 18647268
[TBL] [Abstract][Full Text] [Related]
24. Prevalence, characteristics, and impact of bloating symptoms in patients with irritable bowel syndrome.
Ringel Y; Williams RE; Kalilani L; Cook SF
Clin Gastroenterol Hepatol; 2009 Jan; 7(1):68-72; quiz 3. PubMed ID: 19124113
[TBL] [Abstract][Full Text] [Related]
25. Clinical trial: dextofisopam in the treatment of patients with diarrhoea-predominant or alternating irritable bowel syndrome.
Leventer SM; Raudibaugh K; Frissora CL; Kassem N; Keogh JC; Phillips J; Mangel AW
Aliment Pharmacol Ther; 2008 Jan; 27(2):197-206. PubMed ID: 17973974
[TBL] [Abstract][Full Text] [Related]
26. Platelet serotonin transporter in patients with diarrhea-predominant irritable bowel syndrome both before and after treatment with alosetron.
Bellini M; Rappelli L; Blandizzi C; Costa F; Stasi C; Colucci R; Giannaccini G; Marazziti D; Betti L; Baroni S; Mumolo MG; Marchi S; Del Tacca M
Am J Gastroenterol; 2003 Dec; 98(12):2705-11. PubMed ID: 14687821
[TBL] [Abstract][Full Text] [Related]
27. Distribution of high chromogranin A serum levels in patients with nonmetastatic and metastatic prostate adenocarcinoma.
Sciarra A; Di Silverio F; Autran AM; Salciccia S; Gentilucci A; Alfarone A; Gentile V
Urol Int; 2009; 82(2):147-51. PubMed ID: 19321999
[TBL] [Abstract][Full Text] [Related]
28. [Autonomic nervous system activity in IBS patients estimated by heart rate variability (HRV)].
Dobrek Ł; Friediger J; Furgała A; Thor PJ
Przegl Lek; 2006; 63(9):743-7. PubMed ID: 17479861
[TBL] [Abstract][Full Text] [Related]
29. Increased serum free tryptophan in patients with diarrhea-predominant irritable bowel syndrome.
Christmas DM; Badawy AA; Hince D; Davies SJ; Probert C; Creed T; Smithson J; Afzal M; Nutt DJ; Potokar JP
Nutr Res; 2010 Oct; 30(10):678-88. PubMed ID: 21056283
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of treatment continuation with alosetron by IBS-D severity criteria.
Nicandro JP; Shin P; Chuang E
Curr Med Res Opin; 2012 Mar; 28(3):449-56. PubMed ID: 22313141
[TBL] [Abstract][Full Text] [Related]
31. Chromogranin A as an alternative to 5-hydroxyindoleacetic acid in the evaluation of symptoms during treatment of patients with neuroendocrine Tumors.
Korse CM; Bonfrer JM; Aaronson NK; Hart AA; Taal BG
Neuroendocrinology; 2009; 89(3):296-301. PubMed ID: 18840995
[TBL] [Abstract][Full Text] [Related]
32. Different segmental transit times in patients with irritable bowel syndrome and "normal" colonic transit time: is there a correlation with symptoms?
Bouchoucha M; Devroede G; Dorval E; Faye A; Arhan P; Arsac M
Tech Coloproctol; 2006 Dec; 10(4):287-96. PubMed ID: 17115321
[TBL] [Abstract][Full Text] [Related]
33. The Manitoba Inflammatory Bowel Disease Cohort Study: prolonged symptoms before diagnosis--how much is irritable bowel syndrome?
Burgmann T; Clara I; Graff L; Walker J; Lix L; Rawsthorne P; McPhail C; Rogala L; Miller N; Bernstein CN
Clin Gastroenterol Hepatol; 2006 May; 4(5):614-20. PubMed ID: 16630762
[TBL] [Abstract][Full Text] [Related]
34. Health-related quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome: baseline results from LOGIC (Longitudinal Outcomes Study of Gastrointestinal Symptoms in Canada), a naturalistic study.
Paré P; Gray J; Lam S; Balshaw R; Khorasheh S; Barbeau M; Kelly S; McBurney CR
Clin Ther; 2006 Oct; 28(10):1726-35; discussion 1710-1. PubMed ID: 17157129
[TBL] [Abstract][Full Text] [Related]
35. Reports of "satisfactory relief" by IBS patients receiving usual medical care are confounded by baseline symptom severity and do not accurately reflect symptom improvement.
Whitehead WE; Palsson OS; Levy RL; Feld AD; VonKorff M; Turner M
Am J Gastroenterol; 2006 May; 101(5):1057-65. PubMed ID: 16573774
[TBL] [Abstract][Full Text] [Related]
36. Clinical significance of elevated serum chromogranin A levels.
Syversen U; Ramstad H; Gamme K; Qvigstad G; Falkmer S; Waldum HL
Scand J Gastroenterol; 2004 Oct; 39(10):969-73. PubMed ID: 15513336
[TBL] [Abstract][Full Text] [Related]
37. Predictive factors of irritable bowel syndrome improvement: 1-year prospective evaluation in 400 patients.
Mearin F; Badía X; Balboa A; Benavent J; Caballero AM; Domínguez-Muñoz E; Garrigues V; Piqué JM; Roset M; Cucala M; Figueras M;
Aliment Pharmacol Ther; 2006 Mar; 23(6):815-26. PubMed ID: 16556184
[TBL] [Abstract][Full Text] [Related]
38. Value of different diagnostic criteria for the irritable bowel syndrome among men and women.
Hammer J; Talley NJ
J Clin Gastroenterol; 2008 Feb; 42(2):160-6. PubMed ID: 18209586
[TBL] [Abstract][Full Text] [Related]
39. Correlation of gut hormones with irritable bowel syndrome.
Zhang H; Yan Y; Shi R; Lin Z; Wang M; Lin L
Digestion; 2008; 78(2-3):72-6. PubMed ID: 18948690
[TBL] [Abstract][Full Text] [Related]
40. Food-specific IgG4 antibody-guided exclusion diet improves symptoms and rectal compliance in irritable bowel syndrome.
Zar S; Mincher L; Benson MJ; Kumar D
Scand J Gastroenterol; 2005 Jul; 40(7):800-7. PubMed ID: 16109655
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
